The Joint Vasculitis Registry in German-speaking countries (GeVas) : subgroup analysis of 266 AAV patients
OBJECTIVES: Prospective long-term observational data on the disease course of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) were missing in Germany to date. Therefore, the Joint Vasculitis Registry in German-speaking countries (GeVas) has been established to follow the course of patients with AAV. The aim of this study is to present baseline data of patients with newly diagnosed and relapsing AAV enrolled in the GeVas registry.
METHODS: GeVas is a prospective, web-based, multicentre, clinician-driven registry for the documentation of organ manifestations, damage, long-term outcomes, and therapy regimens in various types of vasculitis. Recruitment started in June 2019.
RESULTS: Between June 2019 and October 2022, 266 patients with AAV were included in the GeVas registry: 173 (65%) with new-onset and 93 (35%) with relapsing AAV. One hundred and sixty-two (61%) patients were classified as granulomatosis with polyangiitis (GPA), 66 (25%) as microscopic polyangiitis (MPA), 36 (13%) as eosinophilic granulomatosis with polyangiitis (EGPA), and 2 (1%) as renal limited AAV. The median age was 59 years (51-70 years, IQR), 130 (51%) patients were female. Most patients were ANCA positive (177; 67%) and affected by general symptoms, pulmonary, ear nose throat (ENT), renal and neurological involvement. For induction of remission, the majority of patients received glucocorticoids (247, 93%) in combination with either rituximab (118, 45%) or cyclophosphamide (112, 42%).
CONCLUSIONS: Demographic characteristics are comparable to those in other European countries. Differences were found regarding ANCA status, frequencies of organ manifestations, and therapeutic regimens. The GeVas registry will allow longitudinal observations and prospective outcome measures in AAV.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Clinical and experimental rheumatology - 42(2024), 4 vom: 29. Apr., Seite 852-858 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arnold, Sabrina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 29.04.2024 Date Revised 29.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.55563/clinexprheumatol/suxkyq |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370969901 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370969901 | ||
| 003 | DE-627 | ||
| 005 | 20240429232151.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.55563/clinexprheumatol/suxkyq |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1392.xml |
| 035 | |a (DE-627)NLM370969901 | ||
| 035 | |a (NLM)38607682 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arnold, Sabrina |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Joint Vasculitis Registry in German-speaking countries (GeVas) |b subgroup analysis of 266 AAV patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.04.2024 | ||
| 500 | |a Date Revised 29.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: Prospective long-term observational data on the disease course of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) were missing in Germany to date. Therefore, the Joint Vasculitis Registry in German-speaking countries (GeVas) has been established to follow the course of patients with AAV. The aim of this study is to present baseline data of patients with newly diagnosed and relapsing AAV enrolled in the GeVas registry | ||
| 520 | |a METHODS: GeVas is a prospective, web-based, multicentre, clinician-driven registry for the documentation of organ manifestations, damage, long-term outcomes, and therapy regimens in various types of vasculitis. Recruitment started in June 2019 | ||
| 520 | |a RESULTS: Between June 2019 and October 2022, 266 patients with AAV were included in the GeVas registry: 173 (65%) with new-onset and 93 (35%) with relapsing AAV. One hundred and sixty-two (61%) patients were classified as granulomatosis with polyangiitis (GPA), 66 (25%) as microscopic polyangiitis (MPA), 36 (13%) as eosinophilic granulomatosis with polyangiitis (EGPA), and 2 (1%) as renal limited AAV. The median age was 59 years (51-70 years, IQR), 130 (51%) patients were female. Most patients were ANCA positive (177; 67%) and affected by general symptoms, pulmonary, ear nose throat (ENT), renal and neurological involvement. For induction of remission, the majority of patients received glucocorticoids (247, 93%) in combination with either rituximab (118, 45%) or cyclophosphamide (112, 42%) | ||
| 520 | |a CONCLUSIONS: Demographic characteristics are comparable to those in other European countries. Differences were found regarding ANCA status, frequencies of organ manifestations, and therapeutic regimens. The GeVas registry will allow longitudinal observations and prospective outcome measures in AAV | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 700 | 1 | |a Wallmeier, Pia |e verfasserin |4 aut | |
| 700 | 1 | |a Tais, Arlette |e verfasserin |4 aut | |
| 700 | 1 | |a Ihorst, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Janoschke, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Schubach, Fabian |e verfasserin |4 aut | |
| 700 | 1 | |a Aries, Peer |e verfasserin |4 aut | |
| 700 | 1 | |a Bergner, Raoul |e verfasserin |4 aut | |
| 700 | 1 | |a Bremer, Jan Phillip |e verfasserin |4 aut | |
| 700 | 1 | |a Görl, Norman |e verfasserin |4 aut | |
| 700 | 1 | |a Gutdeutsch, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Hellmich, Bernhard |e verfasserin |4 aut | |
| 700 | 1 | |a Henes, Jörg |e verfasserin |4 aut | |
| 700 | 1 | |a Hoyer, Bimba Franziska |e verfasserin |4 aut | |
| 700 | 1 | |a Kangowski, Antje |e verfasserin |4 aut | |
| 700 | 1 | |a Kötter, Ina |e verfasserin |4 aut | |
| 700 | 1 | |a Krusche, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Magnus, Tim |e verfasserin |4 aut | |
| 700 | 1 | |a Metzler, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Müller-Ladner, Ulf |e verfasserin |4 aut | |
| 700 | 1 | |a Petersen, Jana |e verfasserin |4 aut | |
| 700 | 1 | |a Reichelt de Tenorio, Anke |e verfasserin |4 aut | |
| 700 | 1 | |a Schaier, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Schirmer, Jan Henrik |e verfasserin |4 aut | |
| 700 | 1 | |a Schönermarck, Ulf |e verfasserin |4 aut | |
| 700 | 1 | |a Thiel, Jens |e verfasserin |4 aut | |
| 700 | 1 | |a Unger, Leonore |e verfasserin |4 aut | |
| 700 | 1 | |a Venhoff, Nils |e verfasserin |4 aut | |
| 700 | 1 | |a Weinmann-Menke, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Iking-Konert, Christof |e verfasserin |4 aut | |
| 700 | 1 | |a Lamprecht, Peter |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental rheumatology |d 1989 |g 42(2024), 4 vom: 29. Apr., Seite 852-858 |w (DE-627)NLM012613010 |x 0392-856X |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:4 |g day:29 |g month:04 |g pages:852-858 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.55563/clinexprheumatol/suxkyq |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 4 |b 29 |c 04 |h 852-858 | ||